Home » Authors » Trista Morrison

Articles by Trista Morrison

Proacta Completes $35M Series B For Hypoxia Trials

Feb. 8, 2007

By Trista Morrison

Proacta Completes $35M Series B For Hypoxia Trials

Feb. 8, 2007

By Trista Morrison

Deal-Making Trend: M&A Activity Continues to Rise

Feb. 7, 2007

By Trista Morrison

Deal-Making Competition Is Up; Winners Offer More Than Money

Feb. 6, 2007

By Trista Morrison

Deal-Making Competition Is Up; Winners Offer More Than Money

Feb. 6, 2007

By Trista Morrison

Ligand Restructures To Focus On Early Pipeline, Royalties

Feb. 2, 2007

By Trista Morrison

Ligand Restructures To Focus On Early Pipeline, Royalties

Feb. 2, 2007

By Trista Morrison

Repros Therapeutics Raising $36M On Positive Interim Data

Feb. 1, 2007

By Trista Morrison

Repros Therapeutics Raising $36M On Positive Interim Data

Feb. 1, 2007

By Trista Morrison

Ception Closes $63M Series C For Anti-Inflammatory Trials

Jan. 31, 2007

By Trista Morrison

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...